Logo image of GANX

GAIN THERAPEUTICS INC (GANX) Stock Fundamental Analysis

USA - NASDAQ:GANX - US36269B1052 - Common Stock

2.83 USD
-0.16 (-5.35%)
Last: 11/14/2025, 8:00:00 PM
2.87 USD
+0.04 (+1.41%)
After Hours: 11/14/2025, 8:00:00 PM
Fundamental Rating

1

Overall GANX gets a fundamental rating of 1 out of 10. We evaluated GANX against 531 industry peers in the Biotechnology industry. Both the profitability and financial health of GANX have multiple concerns. GANX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GANX has reported negative net income.
In the past year GANX has reported a negative cash flow from operations.
GANX had negative earnings in each of the past 5 years.
In the past 5 years GANX always reported negative operating cash flow.
GANX Yearly Net Income VS EBIT VS OCF VS FCFGANX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

GANX has a Return On Assets of -168.36%. This is amonst the worse of the industry: GANX underperforms 87.76% of its industry peers.
The Return On Equity of GANX (-278.10%) is worse than 70.43% of its industry peers.
Industry RankSector Rank
ROA -168.36%
ROE -278.1%
ROIC N/A
ROA(3y)-120.33%
ROA(5y)-86.78%
ROE(3y)-182.77%
ROE(5y)-129.19%
ROIC(3y)N/A
ROIC(5y)N/A
GANX Yearly ROA, ROE, ROICGANX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

GANX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GANX Yearly Profit, Operating, Gross MarginsGANX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K

More info and screens

3

2. Health

2.1 Basic Checks

GANX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GANX has been increased compared to 1 year ago.
The number of shares outstanding for GANX has been increased compared to 5 years ago.
GANX has a worse debt/assets ratio than last year.
GANX Yearly Shares OutstandingGANX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
GANX Yearly Total Debt VS Total AssetsGANX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

GANX has an Altman-Z score of -0.67. This is a bad value and indicates that GANX is not financially healthy and even has some risk of bankruptcy.
GANX has a Altman-Z score (-0.67) which is in line with its industry peers.
A Debt/Equity ratio of 0.04 indicates that GANX is not too dependend on debt financing.
GANX has a Debt to Equity ratio (0.04) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -0.67
ROIC/WACCN/A
WACC8.75%
GANX Yearly LT Debt VS Equity VS FCFGANX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

GANX has a Current Ratio of 2.97. This indicates that GANX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of GANX (2.97) is worse than 63.84% of its industry peers.
A Quick Ratio of 2.97 indicates that GANX has no problem at all paying its short term obligations.
GANX's Quick ratio of 2.97 is on the low side compared to the rest of the industry. GANX is outperformed by 61.96% of its industry peers.
Industry RankSector Rank
Current Ratio 2.97
Quick Ratio 2.97
GANX Yearly Current Assets VS Current LiabilitesGANX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

GANX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.01%, which is quite impressive.
GANX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)54.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.76%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 10.02% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y27.93%
EPS Next 2Y7.98%
EPS Next 3Y6.24%
EPS Next 5Y10.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GANX Yearly Revenue VS EstimatesGANX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2029 2030 2031 2032 100M 200M 300M
GANX Yearly EPS VS EstimatesGANX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GANX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GANX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GANX Price Earnings VS Forward Price EarningsGANX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GANX Per share dataGANX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.98%
EPS Next 3Y6.24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GANX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GAIN THERAPEUTICS INC

NASDAQ:GANX (11/14/2025, 8:00:00 PM)

After market: 2.87 +0.04 (+1.41%)

2.83

-0.16 (-5.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2025-11-07
Earnings (Next)03-25 2026-03-25/amc
Inst Owners10.56%
Inst Owner Change1.37%
Ins Owners3.64%
Ins Owner Change0%
Market Cap101.74M
Revenue(TTM)N/A
Net Income(TTM)-20.41M
Analysts84.62
Price Target8.16 (188.34%)
Short Float %3.67%
Short Ratio1.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.83%
Min EPS beat(2)22.48%
Max EPS beat(2)41.18%
EPS beat(4)3
Avg EPS beat(4)-3.99%
Min EPS beat(4)-105.88%
Max EPS beat(4)41.18%
EPS beat(8)4
Avg EPS beat(8)-13.95%
EPS beat(12)6
Avg EPS beat(12)-8.59%
EPS beat(16)8
Avg EPS beat(16)-12.45%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.7%
PT rev (3m)-5.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)1.02%
EPS NY rev (3m)-4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 13.86
P/tB 14.12
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0
BVpS0.2
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -168.36%
ROE -278.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.33%
ROA(5y)-86.78%
ROE(3y)-182.77%
ROE(5y)-129.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.75%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.97
Quick Ratio 2.97
Altman-Z -0.67
F-Score1
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)81.72%
Cap/Depr(5y)179.04%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.76%
EPS Next Y27.93%
EPS Next 2Y7.98%
EPS Next 3Y6.24%
EPS Next 5Y10.02%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.04%
OCF growth 3YN/A
OCF growth 5YN/A

GAIN THERAPEUTICS INC / GANX FAQ

Can you provide the ChartMill fundamental rating for GAIN THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to GANX.


What is the valuation status for GANX stock?

ChartMill assigns a valuation rating of 0 / 10 to GAIN THERAPEUTICS INC (GANX). This can be considered as Overvalued.


Can you provide the profitability details for GAIN THERAPEUTICS INC?

GAIN THERAPEUTICS INC (GANX) has a profitability rating of 0 / 10.


What is the financial health of GAIN THERAPEUTICS INC (GANX) stock?

The financial health rating of GAIN THERAPEUTICS INC (GANX) is 3 / 10.


What is the expected EPS growth for GAIN THERAPEUTICS INC (GANX) stock?

The Earnings per Share (EPS) of GAIN THERAPEUTICS INC (GANX) is expected to grow by 27.93% in the next year.